Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Vascular Effects of Adrenomedullin and the Anti-Adrenomedullin Antibody Adrecizumab in Sepsis
Christopher Geven, Andreas Bergmann, Matthijs Kox, et al.
Shock (2018) Vol. 50, Iss. 2, pp. 132-140
Closed Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Adrenomedullin in heart failure: pathophysiology and therapeutic application
Adriaan A. Voors, Daan Kremer, Christopher Geven, et al.
European Journal of Heart Failure (2018) Vol. 21, Iss. 2, pp. 163-171
Open Access | Times Cited: 189
Regulation and Dysregulation of Endothelial Permeability during Systemic Inflammation
Katharina E. M. Hellenthal, Laura Brabenec, Nana‐Maria Wagner
Cells (2022) Vol. 11, Iss. 12, pp. 1935-1935
Open Access | Times Cited: 101
Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology
Julio Núñez, Rafael de la Espriella, Patrick Rossignol, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 10, pp. 1751-1766
Open Access | Times Cited: 93
COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure
Monia Marchetti
Annals of Hematology (2020) Vol. 99, Iss. 8, pp. 1701-1707
Open Access | Times Cited: 132
Adrenomedullin and Adrenomedullin-Targeted Therapy As Treatment Strategies Relevant for Sepsis
Christopher Geven, Matthijs Kox, Peter Pickkers
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 112
Bio‐adrenomedullin as a marker of congestion in patients with new‐onset and worsening heart failure
Jozine M. ter Maaten, Daan Kremer, Biniyam G. Demissei, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 6, pp. 732-743
Open Access | Times Cited: 89
Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial
Pierre‐François Laterre, Peter Pickkers, Gernot Marx, et al.
Intensive Care Medicine (2021) Vol. 47, Iss. 11, pp. 1284-1294
Open Access | Times Cited: 67
Clinical Potential of Adrenomedullin Signaling in the Cardiovascular System
László Bálint, Nathan Nelson-Maney, Yanna Tian, et al.
Circulation Research (2023) Vol. 132, Iss. 9, pp. 1185-1202
Closed Access | Times Cited: 21
The Apelin/APJ System: A Potential Therapeutic Target for Sepsis
Qing Song, Xi Wang, Zhenhuan Cao, et al.
Journal of Inflammation Research (2024) Vol. Volume 17, pp. 313-330
Open Access | Times Cited: 6
Clinical value of pre‐discharge bio‐adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission
Paloma Pandhi, Jozine M. ter Maaten, Johanna E. Emmens, et al.
European Journal of Heart Failure (2019) Vol. 22, Iss. 4, pp. 683-691
Open Access | Times Cited: 46
A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2)
Christopher Geven, Alice Blet, Matthijs Kox, et al.
BMJ Open (2019) Vol. 9, Iss. 2, pp. e024475-e024475
Open Access | Times Cited: 44
Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness
Oscar Lundberg, Maria Lengquist, Martin Spångfors, et al.
Critical Care (2020) Vol. 24, Iss. 1
Open Access | Times Cited: 41
Adrenomedullin: Continuing to explore cardioprotection
Toshihiro Tsuruda, Johji Kato, Kenji Kuwasako, et al.
Peptides (2018) Vol. 111, pp. 47-54
Closed Access | Times Cited: 45
Effects of the Humanized Anti-Adrenomedullin Antibody Adrecizumab (HAM8101) on Vascular Barrier Function and Survival in Rodent Models of Systemic Inflammation and Sepsis
Christopher Geven, Esther Peters, Mathias Schroedter, et al.
Shock (2018) Vol. 50, Iss. 6, pp. 648-654
Open Access | Times Cited: 44
Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first‐in‐human study and during experimental human endotoxaemia in healthy subjects
Christopher Geven, Dirk van Lier, Alice Blet, et al.
British Journal of Clinical Pharmacology (2018) Vol. 84, Iss. 9, pp. 2129-2141
Open Access | Times Cited: 44
Promotion of vascular integrity in sepsis through modulation of bioactive adrenomedullin and dipeptidyl peptidase 3
Dirk van Lier, Matthijs Kox, Peter Pickkers
Journal of Internal Medicine (2020) Vol. 289, Iss. 6, pp. 792-806
Open Access | Times Cited: 34
Adrenomedullin improved endothelial dysfunction via receptor-Akt pathway in rats with obesity-related hypertension
Siyu Liu, Qian Wang, Ye‐Bo Zhou, et al.
Hypertension Research (2024) Vol. 47, Iss. 8, pp. 2157-2171
Closed Access | Times Cited: 4
The ADESTE trial: A phase 2 study of enibarcimab, a monoclonal antibody targeting adrenomedullin, in acute heart failure
Anggoro Budi Hartopo, Arinal Chairul Achyar, Hendry Purnasidha Bagaswoto, et al.
ESC Heart Failure (2025)
Open Access
Biomarkers for Congestion in Heart Failure: State-of-the-art and Future Directions
Antonio Luca Maria Parlati, Cristina Madaudo, Vincenzo Nuzzi, et al.
Cardiac failure review (2025) Vol. 11
Open Access
Enibarcimab for the treatment of septic shock in patients selected by a combination of the biomarkers bio-ADM and DPP3: A prespecified subgroup analysis of the AdrenOSS-2 trial
Claudia Knothe, Stephan Witte, Andreas Bergmann, et al.
Journal of Critical Care (2025) Vol. 88, pp. 155077-155077
Closed Access
Natural and synthetic peptides in the cardiovascular diseases: An update on diagnostic and therapeutic potentials
Paolo Grieco, Isabel Gómez‐Monterrey
Archives of Biochemistry and Biophysics (2018) Vol. 662, pp. 15-32
Open Access | Times Cited: 33
High value of mid‐regional proadrenomedullin in COVID‐19: A marker of widespread endothelial damage, disease severity, and mortality
Silvia Spoto, Felice Eugenio Agrò, Federica Sambuco, et al.
Journal of Medical Virology (2020) Vol. 93, Iss. 5, pp. 2820-2827
Open Access | Times Cited: 32
Bioactive adrenomedullin, proenkephalin A and clinical outcomes in an acute heart failure setting
John Molvin, Amra Jujić, Silvia Navarin, et al.
Open Heart (2019) Vol. 6, Iss. 2, pp. e001048-e001048
Open Access | Times Cited: 30
New Agents in Development for Sepsis: Any Reason for Hope?
Philippe Vignon, Pierre‐François Laterre, Thomas Daix, et al.
Drugs (2020) Vol. 80, Iss. 17, pp. 1751-1761
Open Access | Times Cited: 29
Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial
Mahir Karakas, İbrahim Akın, Christoph Burdelski, et al.
The Lancet Respiratory Medicine (2021) Vol. 10, Iss. 3, pp. 247-254
Closed Access | Times Cited: 24
Page 1 - Next Page

Scroll to top